News / Taiwan / economic_daily
Adimmune Subsidiary Enters Thai Market with EV71 Vaccine Partnership
Health Technology · Biotechnology · economic_daily · 2026-09-23
6564
Adimmune's subsidiary, Enimmune, has signed an exclusive distribution deal with Thailand's Biogenetech to supply EV71 vaccines to the Thai market.
What Happened
Partnership Agreement: Enimmune, a subsidiary of the Adimmune Corporation, has signed an exclusive distribution agreement with Thai biopharmaceutical leader Biogenetech for its Enterovirus 71 (EV71) vaccine. The collaboration aims to introduce high-efficacy vaccines to Thailand, addressing critical gaps in local public health prevention.
Market Potential: Thailand's high-risk population of children aged 0-4 is approximately 2.64 million, with an additional 400,000 newborns annually, representing a significant market opportunity. Enimmune expects to target both public and private sectors, potentially serving up to 3 million infants.
Strategic Partner: Biogenetech, with over 30 years of experience in Thailand, brings extensive regulatory expertise and a proven track record of international partnerships. Their nationwide cold-chain logistics network and direct access to major hospitals and clinics provide a strong foundation for vaccine distribution.
Strategic Significance: This expansion into Thailand marks a major milestone for Enimmune's growth in Southeast Asia. By leveraging the local partner's established infrastructure, Enimmune aims to rapidly penetrate the market and enhance the international presence of its EV71 vaccine.
Read original
More in Health Technology
Health Technology · economic_daily · 2026-09-23
PharmaEssentia is establishing an Australian base to initiate regulatory approval processes for its flagship drug, Ropeg, in the local market.
6446
Health Technology · economic_daily · 2026-09-23
OBI Pharma's stock staged a strong recovery today, climbing from an early low to hit the daily limit up, sparking speculation about potential positive developments.
Health Technology · economic_daily · 2026-09-23
Taiwan's health ministry plans to cut new drug approval times to 100 days, sparking a rally in local biotech stocks like TLC-KY amid improved regulatory outlooks.
4174, 6610, 6696, 6838, 7924
Latest in Taiwan
Electronic Technology · economic_daily · 2026-09-23
Zhen Ding Tech has successfully priced an $800 million overseas convertible bond, drawing over seven times the demand from global institutional investors.
4958
Electronic Technology · economic_daily · 2026-09-23
Taiwan's stock market reached a historic milestone, closing above 48,000 points with a market cap of $5.3 trillion, as analysts eye the 50,000-point mark.
2330, 2368, 2404, 2454, 3443, 3653, 6488, 6805
Finance · economic_daily · 2026-09-23
Taiwan's central bank reported a record high in securities deposits for August, fueled by record-breaking corporate dividend payouts and resilient retail participation.
Electronic Technology · economic_daily · 2026-09-23
Driven by robust AI demand and steady ETF inflows, analysts are bullish on Taiwan stocks, with some projecting the index to hit 55,000 by year-end.